Residence structures and related methods
Certain embodiments comprise administering a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. In certain embodiments, the structure has a modular design, combining a material configured for controlled release of therapeutic, diagnostic, and/or enhancement agents with a structural material necessary for gastric residence but configured for controlled and/or tunable degradation/dissolution to determine the time at which retention shape integrity is lost and the structure passes out of the gastric cavity. For example, in certain embodiments, the residence structure comprises a first elastic component, a second component configured to release an active substance, and, optionally, a linker. In some such embodiments, the linker may be configured to degrade.
1. A gastric residence structure, comprising:
a containing structure; and
a gastric residence structure contained within the containing structure, the gastric residence structure comprising:
a first polymeric component;
a second polymeric component coupled to the first polymeric component; and
at least one degradable linker coupled with the first polymeric component,
wherein the gastric residence structure is constructed and arranged to have a first configuration when constrained by the containing structure, and configured to undergo a change in shape upon release from the containing structure in the stomach to assume a second configuration, wherein change between the first configuration and the second configuration is mediated by the second polymeric component that undergoes elastic deformation when the gastric residence structure is in the first configuration and recoils when the gastric residence structure assumes the second configuration,
wherein the first polymeric component and/or second polymeric component comprises an active substance or salt thereof,
and
wherein the gastric residence structure has a cross-sectional area having a shape selected from the group consisting of square, circle, oval, polygon, tubes, and rings.
2. The gastric residence structure as in claim 1 , wherein the at least one degradable linker is selected such that the linker dissolves, degrades, mechanically weakens, and/or mechanically separates from at least one of the one or more polymeric components and mediates exit of the gastric residence structure from a location of a subject.
3. The gastric residence structure as in claim 1 , wherein the second polymeric component is free of active substance.
4. The gastric residence structure as in claim 1 , wherein the second polymeric component is an elastic polymeric component.
5. The gastric residence structure as in claim 1 , wherein the structure is configured such that it is retained at the location internally of the subject for at least about 24 hours in the second configuration.
6. The gastric residence structure as in claim 3 , wherein the structure releases between about 0.05 wt % and about 50 wt % of the active substance during a first day of release.
7. The gastric residence structure as in claim 3 , wherein the first polymeric comprises at least 10 wt % active substance of the total weight of the first polymeric component.
8. The gastric residence structure as in claim 1 , wherein at least one degradable linker comprises an enteric polymer.
9. The gastric residence structure as in claim 1 , wherein the gastric residence structure is retained in the stomach for at least about 1 week.
10. The gastric residence structure as in claim 1 , wherein the gastric residence structure can be retained in the stomach for at least about 48 hours in the second configuration.
11. The gastric residence structure as in claim 2 , wherein the separate degradable linker, after at least about 48 hours, degrades, dissolves, disassociates, and/or mechanically weakens in the gastric environment under gastrointestinal physiological conditions which results in loss of the second configuration and passage of the gastric residence structure out of the stomach through the gastric pyloric orifice.
12. The gastric residence structure as in claim 1 , wherein the active substance is a biological macromolecule, a small molecule, a vitamin, or a supplement.
13. The gastric residence structure as in claim 1 , wherein the active substance is a selective serotonin reuptake inhibitor, a blood thinning agent, a steroid, an antagonist, a cardiac glycoside, an alpha blocker, a cholesterol absorption inhibitor, a metabolite, an antihistamine, an opioid, a proton-pump inhibitor, an antibiotic, an anti-malarial agent, sulfonamides, a substance abuse treatment, a contraceptive, a stimulant, an analgesic, an anti-analgesic, an anti-inflammatory drug, a nonsteroidal anti-inflammatory drug, an antipyretic, an immunosuppressant, a neuroprotective agent, an antipsychotic, a statin, an antidepressant, an antiepileptic, an anti-proliferative, an anti-cancer agent, an antimigraine drug, an antimicrobial, an antifungal, an antiviral agent, an antiretroviral agent, an antiparasitic, an antimuscarinic, an anxiolytic, a bacteriostatic, a sedative, a hypnotic, a bronchodilator, an anti-asthma drug, a cardiovascular drug, an anesthetic, an anticoagulant, a dopaminergic, an electrolyte, a gastro-intestinal drug, a muscle relaxant, a parasympathomimetic, an anorectic, an anti-narcoleptic, a protein, a peptide, a hormone, a nucleic acid, a gene construct, 3-hydroxy-3-methyl-glutaryl (HMG) co-A reductase inhibitor, a mineral, a prostaglandin, a nutritional supplement, a corticosteroid, a nutraceutical, a plant extract, or a phytohormone.
14. The gastric residence structure as in claim 1 , wherein the active substance is a selective serotonin reuptake inhibitor, an antidepressant, an anxiolytic, a sedative, a hypnotic, an opioid, an antimigraine drug, a cholesterol absorption inhibitor, a substance abuse treatment, an immunosuppressant, an HMG co-A reductase inhibitor, a blood thinning agent, a cardiac glycoside, an antibiotic, a contraceptive, an analgesic, an anesthetic, a nonsteroidal anti-inflammatory drug, an antiepileptic, or an alpha blocker.
15. The gastric residence structure as in claim 1 , wherein the active substance is meloxicam, escitalopram, clopidogrel, prasugrel, prednisone, naloxone, montelukast, digoxin, tamsulosin, ezetimibe, colchicine, loratadine, cetirizine, loperamide, omeprazole, entecavir, ciprofloxacin, azithromycin, quinine, lumefantrine, chloroquine, amodiaquine, pyrimethamine, proguanil, chlorproguanil-dapsone, sulfadoxine, sulfamethoxypyridazine, mefloquine, atovaquone, primaquine, halofantrine, clindamycin, artemisinin, artemisinin derivatives, artemether, dihydroartemisinin, arteether, artesunate, synthroid/levothyroxine, varenicline, risperidone, memantine, methadone, rosuvastatin, doxycycline, buprenorphine, aripiprazole, caffeine, folic acid, calcium, iodine, iron, zinc, thiamine, niacin, vitamin C, or vitamin D.
16. The gastric residence structure as in claim 1 , wherein the active substance is prednisone, risperidone, memantine, methadone, rosuvastatin, doxycycline, buprenorphine, aripiprazole, meloxicam, or azithromycin.
17. The gastric residence structure as in claim 1 , wherein the active substance is entrapped within a polymer matrix of the first polymeric component.
18. A gastric residence structure as in claim 1 , wherein the active substance is chemically bonded to a polymer of the first polymeric component.
19. The gastric residence structure as in claim 1 , wherein the first polymeric component comprises polycaprolactone (PCL).
20. A gastric residence structure as in claim 1 , wherein the first polymeric component comprises, poly(ethylene-co-vinyl acetate), or polyethylene glycol (PEG).
21. The gastric residence structure as in claim 3 , wherein the active substance is loaded into the first polymeric component by a process comprising powder mixing, solvent loading, melt loading, or physical blending.
22. The gastric residence structure as in claim 1 , comprising two or more degradable linkers.
23. A gastric residence structure, comprising:
a containing structure; and
a gastric residence structure contained within the containing structure, the gastric residence structure comprising:
a first polymeric component;
a second polymeric component coupled to the first polymeric component; and
at least one degradable linker coupled with the first polymeric component,
wherein at least one degradable linker degrades, dissolves, disassociates, or mechanically weakens in a gastric environment which results in loss of retention shape integrity and passage out of a gastric cavity,
wherein the gastric residence structure is constructed and arranged to have a first configuration when constrained by the containing structure, and configured to undergo a change in shape upon release from the containing structure in the stomach to assume a second configuration, wherein change between the first configuration and the second configuration is mediated by the second polymeric component that undergoes elastic deformation when the gastric residence structure is in the first configuration and recoils when the gastric residence structure assumes the second configuration,
wherein the structure is configured such that it is retained at a location internally of a subject for at least about 24 hours, and
wherein the gastric residence structure has a cross-sectional area having a shape selected from the group consisting of square, circle, oval, polygon, tubes, and rings.
24. The gastric residence structure as in claim 23 , wherein the first polymeric component comprises a loadable polymeric material.
25. The gastric residence structure as in claim 23 , wherein the second polymeric component is free of active substance.
26. The gastric residence structure as in claim 23 , wherein the second polymeric component is an elastic polymeric component.
27. The gastric residence structure as in claim 24 , wherein the first polymeric component comprises an active substance or salt thereof.
28. The gastric residence structure as in claim 27 , wherein the structure releases between about 0.05 wt % and about 50 wt % of the active substance during a first day of release.
29. The gastric residence structure as in claim 27 , wherein the first polymeric comprises at least 10 wt % active substance of the total weight of the first polymeric component.
30. The gastric residence structure as in claim 23 , wherein at least one degradable linker comprises an enteric polymer.
31. The gastric residence structure as in claim 23 , wherein the gastric residence structure is retained in the stomach for at least about 1 week.
32. The gastric residence structure as in claim 23 , wherein the degradable linker, after at least about 48 hours, degrades, dissolves, disassociates, and/or mechanically weakens in the gastric environment under gastrointestinal physiological conditions which results in loss of the second configuration and passage of the gastric residence structure out of the stomach through the gastric pyloric orifice.
33. The gastric residence structure as in claim 27 , wherein the active substance is a biological macromolecule, a small molecule, a vitamin, or a supplement.
34. The gastric residence structure as in claim 27 , wherein the active substance is a selective serotonin reuptake inhibitor, a blood thinning agent, a steroid, an antagonist, a cardiac glycoside, an alpha blocker, a cholesterol absorption inhibitor, a metabolite, an antihistamine, an opioid, a proton-pump inhibitor, an antibiotic, an anti-malarial agent, sulfonamides, a substance abuse treatment, a contraceptive, a stimulant, an analgesic, an anti-analgesic, an anti-inflammatory drug, a nonsteroidal anti-inflammatory drug, an antipyretic, an immunosuppressant, a neuroprotective agent, an antipsychotic, a statin, an antidepressant, an antiepileptic, an anti-proliferative, an anti-cancer agent, an antimigraine drug, an antimicrobial, an antifungal, an antiviral agent, an antiretroviral agent, an antiparasitic, an antimuscarinic, an anxiolytic, a bacteriostatic, a sedative, a hypnotic, a bronchodilator, an anti-asthma drug, a cardiovascular drug, an anesthetic, an anticoagulant, a dopaminergic, an electrolyte, a gastro-intestinal drug, a muscle relaxant, a parasympathomimetic, an anorectic, an anti-narcoleptic, a protein, a peptide, a hormone, a nucleic acid, a gene construct, 3-hydroxy-3-methyl-glutaryl (HMG) co-A reductase inhibitor, a mineral, a prostaglandin, a nutritional supplement, a corticosteroid, a nutraceutical, a plant extract, or a phytohormone.
35. The gastric residence structure as in claim 27 , wherein the active substance is a selective serotonin reuptake inhibitor, an antidepressant, an anxiolytic, a sedative, a hypnotic, an opioid, an antimigraine drug, a cholesterol absorption inhibitor, a substance abuse treatment, an immunosuppressant, an HMG co-A reductase inhibitor, a blood thinning agent, a cardiac glycoside, an antibiotic, a contraceptive, an analgesic, an anesthetic, a nonsteroidal anti-inflammatory drug, an antiepileptic, or an alpha blocker.
36. The gastric residence structure as in claim 27 , wherein the active substance is meloxicam, escitalopram, clopidogrel, prasugrel, prednisone, naloxone, montelukast, digoxin, tamsulosin, ezetimibe, colchicine, loratadine, cetirizine, loperamide, omeprazole, entecavir, ciprofloxacin, azithromycin, quinine, lumefantrine, chloroquine, amodiaquine, pyrimethamine, proguanil, chlorproguanil-dapsone, sulfadoxine, sulfamethoxypyridazine, mefloquine, atovaquone, primaquine, halofantrine, clindamycin, artemisinin, artemisinin derivatives, artemether, dihydroartemisinin, arteether, artesunate, synthroid/levothyroxine, varenicline, risperidone, memantine, methadone, rosuvastatin, doxycycline, buprenorphine, aripiprazole, caffeine, folic acid, calcium, iodine, iron, zinc, thiamine, niacin, vitamin C, or vitamin D.
37. The gastric residence structure as in claim 27 , wherein the active substance is prednisone, risperidone, memantine, methadone, rosuvastatin, doxycycline, buprenorphine, aripiprazole, meloxicam, or azithromycin.
38. The gastric residence structure as in claim 27 , wherein the active substance is entrapped within a polymer matrix of the first polymeric component.
39. A gastric residence structure as in claim 30 , wherein the active substance is chemically bonded to a polymer of the first polymeric component.
40. The gastric residence structure as in claim 23 , wherein the first polymeric component comprises polycaprolactone (PCL).
41. A gastric residence structure as in claim 23 , wherein the first polymeric component comprises, poly(ethylene-co-vinyl acetate), or polyethylene glycol (PEG).
42. The gastric residence structure as in claim 27 , wherein the active substance is loaded into the loadable polymeric material by a process comprising powder mixing, solvent loading, melt loading, or physical blending.
43. The gastric residence structure as in claim 23 , comprising two or more degradable linkers.
44. The gastric residence structure as in claim 43 , wherein at least one degradable linker is a time dependent degradable linker.
45. The gastric residence structure as in claim 43 , wherein at least one degradable linker comprises an enteric polymer.